University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.
Icosavax, a US-based vaccine developer based on research at University of Washington (UW), filed for an initial public offering on Tuesday with a $100m placeholder target.
The company hopes to list on the Nasdaq Global Select Market under the symbol ICVX. It has not yet set any terms for the proposed offering.
Founded in 2017, Icosavax is working on vaccines for infectious diseases that cause life-threatening respiratory illnesses. Its pipeline includes IVX-A12 and IVX-411, candidates aimed at respiratory syncytial virus and Sars-CoV-2, respectively.
The spinout has also signed a licensing agreement with University of Texas at Austin to develop a vaccine aimed at human metapneumovirus. Icosavax’s original research is based on work by co-founders Neil King and David Baker at UW’s Institute of Protein Design.
Proceeds from the offering would go towards the continued development of its current pipeline, including further progressing IVX-A12 and IVX-411…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
